obesity drug news today glp-1 october 2025 Outlook for obesity in 2025: more than a transition year Beyond GLP-1: the next wave
Description
10.1016/S0140-6736(23)01289-8 36 KapoorI.SarvepalliS
Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors
The complex pathophysiology and the metabolic risk factors shared between type 2 diabetes, obesity, CKD and cardiovascular disease have led to the concept of a cardiovascularkidneymetabolic (CKM) syndrome
It does not, on the evidence we have today, replace the injection for every patient
